Clinical Study
The Effectiveness of Liraglutide in Nonalcoholic Fatty Liver Disease Patients with Type 2 Diabetes Mellitus Compared to Sitagliptin and Pioglitazone
Table 4
Change of parameters after administration of pioglitazone.
| | Pioglitazone group (N = 20) | | | Variables (N) | Before administration | After administration | Paired t-test | | P value |
| | Body weight* (kg) | 78.6 (68.2–86.0) | 81.8 (73.0–86.8) | <0.01 | | BMI* (kg/m2) | 28.8 (24.6–31.5) | 30.0 (26.2–33.9) | 0.02 | | AST* (IU/mL) | 62 (40–85) | 41 (26–47) | <0.01 | | ALT* (IU/mL) | 87 (60–112) | 53 (33–69) | <0.01 | | γ-GTP* (IU/mL) | 95 (54–114) | 65 (31–87) | <0.01 | | Fast blood glucose* (mg/dL) | 182 (135–224) | 141 (114–161) | <0.01 | | HbA1c (%) | 7.7 (6.9–8.5) | 6.9 (6.2–7.3) | <0.01 | | LDL-cholesterol* (mg/dL) | 114 (92–140) | 114 (87–140) | 0.78 | | Triglyceride* (mg/dL) | 210 (130–198) | 161 (95–165) | 0.03 | | Platelet count* (/μL) | 193 (147–233) | 184 (138–226) | 0.14 | | APRI index* | 0.96 (0.60–1.09) | 0.73 (0.41–0.71) | 0.01 |
|
|
BMI: body mass index; AST: aspartate aminotransferase; ALT: alanine aminotransferase; γ-GTP: γ-glutamyl transpeptidase; HbA1c: hemoglobin A1c; APRI: AST-to-platelet counts ratio index.
|
